MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF. The patent stems from a provisional patent application filed in the USPTO in 2000 by the University of Melbourne. In
Full Post: MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders
Covidien has announced that it is launching a new and improved Magellan Safety Hypodermic Needle.
The development of the new design, which gives clinicians more control and smoother activation of the safety shield, reflects Covidien’s continued commitment to improving healthcare worker safety.
“We are transitioning to the new and improved Magellan Safety Needle technology as part of our strong and ongoing commitment to meeting the safety needs of our customers,” said Jeff Hunt, President, Patient Care and Safety Products, Covidien. “As you may know, there is litigation under way related to the current Magellan Safety Needle technology used on our Magellan family of products. We are optimistic that the litigation will ultimately be resolved in our favor,” Hunt added.
Covidien also announced that it has appealed a U.S. District Court jury finding in November 2007 that Covidien’s current Magellan Safety Needle products infringed one of Becton Dickinson’s patents and a subsequent judge’s ruling granting Becton Dickinson’s request for an injunction against Covidien’s current Magellan Safety Needle product line. The injunction is scheduled to take effect on December 17, 2008. Over the next several weeks, Covidien will transition from its current line to its new and improved Safety Needle products.
“While we respect the judge’s recent ruling in this matter, we believe our current product line does not infringe on Becton Dickinson’s intellectual property,” Hunt said. “Our number one priority is to ensure that our customers receive the very best in needle safety protection. We will continue to provide the best solutions in healthcare worker protection as we seamlessly transition to the new and improved Magellan Safety Needles.”
Net sales of the Magellan product line were less than $35 million in fiscal 2008.
http://www.covidien.com
--------------------------------------------------------------------------------------------
Related Posts:
Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares’ needle-free injection devices with its human growth hormone (hGH), Zomacton. Ferring has been notified recently that the mutual recognition process for European member states has been positively concluded for the Zomacton
Full Post: Needle-free injection device approved in Europe and Australia
Arteriocyte announced today a $1,950,000 award from DARPA for the company’s Nanofiber Based System (NANEX) technology for the Production of Red Blood Cells project. DARPA’s Blood Pharming program aims to develop an automated culture and packaging system that will yield a readily available, donorless supply of universal donor red blood cells in the military
Full Post: Arteriocyte awarded DARPA funding for company’s blood pharming technology
Watson Pharmaceuticals, Inc. has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, coated mint flavor, in the 2 mg and 4 mg strengths. Nicotine Polacrilex Gum, coated mint flavor, is the generic equivalent of GlaxoSmithKline Consumer Healthcare’s Nicorette (R) fresh mint gum, which is used
Full Post: Watson Pharmaceuticals receives FDA approval for mint coated nicotine gum
SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations. SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the
Full Post: SurModics acquires drug delivery assets of PR Pharmaceuticals
Mylan Inc. has announced that its subsidiary, Mylan Pharmaceuticals Inc., received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, 10 mg and 20 mg. Fluoxetine Capsules, indicated for the treatment of premenstrual dysphoric disorder (PMDD) are the generic version of Eli Lilly’s
Full Post: Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules --------------------------------------------------------------------------------------------
